A sensitive biomarker developed at an Israeli medical diagnostic and biotechnology company in Yokneam is the first in the world believed to predict during early pregnancy the chance a woman will develop preeclampsia, a condition which involves high blood pressure and can lead to complications in the kidneys, liver, blood system and brain, as well as to premature delivery.
Called placental protein 13 (PP13), the biomarker was developed at Diagnostic Technologies Ltd. (DTL), made available for a fee to some Israeli women and will now be tested further in Austria.
Prof. Berthold Huppertz, a German-born cell biology expert at the Institute of Cell Biology, History and Embryology at the University of Graz in Austria, said he would collaborate with obstetricians at the university women's hospital in the city to test the Israeli biomarker. DTL began as an "incubator" project at the Technion-Israel Institute of Technology in 1994. It became a fully-fledged company eight years ago, but is currently seeking more investors.
Lire la suite »
Source: article de Judy Siegel-Itzkovich @ TJP